Drug Research
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
WuXi Biologics , a leading global Contract Research, Development, and Manufacturing Organization announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary...
Press Releases
TMC Pharma Appoints Industry Veteran To Board
TMC Pharma Services, an international Pharmaceutical Development Organisation specialising in Orphan Drug development, has appointed Gordon Cameron as a Non-Executive Director to support the growth of the business.
Gordon brings 25 years’ board-level experience in in the biotech and pharmaceutical...
Press Releases
Hetero’s ‘NIRMACOM’ is world’s first generic version of COVID-19 oral drug PAXLOVID to receive WHO Prequalification
Hetero, India’s leading pharmaceutical company with the widest global reach, announced the receipt of World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate nirmatrelvir. This is the first...
Press Releases
WuXi STA Launches First Continuous Manufacturing Line for Oral Solids
WuXi STA, a subsidiary of WuXi AppTec, announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at the drug product site located in Wuxi city, China. This new CM line provides global...
Press Releases
Aptar Pharma Multidose Device Delivers Approved Human Monoclonal Antibody Anti-COVID Nasal Spray in Thailand
Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that its VP7 nasal multidose device is the delivery system for Hibiocy’s VAILL COVITRAP™ Anti-CoV nasal spray, which was recently approved by the...
Press Releases
Clinical trial platform provider encapsia welcomes new COO
Clinical trial management solutions provider, encapsia, has announced the appointment of Francis Destin as its new Chief Operating Officer. Francis brings more than 20 years of expertise to the role, specialising in the management of data-related projects in clinical...
Drug Research
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services.
By using...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















